The affected mandate requires that all newborns receive erythromycin ointment applied to their eyes after birth, which helps prevent ophthalmia neonatorum.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Inflammation is both a cause and consequence of dry eye disease.

The VLP system, engineered nucleocytosolic vehicle for loading of programmable editors (ENVLPE), was found to have corrected 2 mutations associated with blindness.

The program also offers eligible students with an in-school commitment to hire them after graduation and provides support for federal and private loans.

CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.

The award recognizes CooperVision for its support of educational opportunities for students, including the sponsorship of a new eye care clinic.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, lectured on retinal updates at CRU 2025. The pair also covered the power of a low vision referral for patients with retinal disease.

The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.

Following a discussion on low-dose atropine, Paul Karpecki, OD, FAAO, shares his views on what the future of myopia management looks like.

Topline data from both phase 3 trials are expected in the second quarter of 2026, with NDA submission to follow thereafter.

Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.

Educational tools, visual aids can help children with visual impairments thrive.

Catch up on the top stories in optometry during the week of April 7-April 11.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

CLI Visionaries provide professional perspectives on best practices and highlight the EASY (Eyes, Awareness, Safety & You) Way program in the series.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

The Vision Council report highlights providers’ expectations and the perceived impact of economic factors including tariffs, inflation, staffing and hiring, and technological integration including telehealth and artificial intelligence.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, detailed the prevalence of the conditions, diagnostic tools, and treatment options.